<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850848</url>
  </required_header>
  <id_info>
    <org_study_id>YSP RHH3001-01</org_study_id>
    <nct_id>NCT02850848</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Two Formulations of Entecavir</brief_title>
  <official_title>A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of a Test Formulation of Entigin Film Coated Tablet 0.5mg (Entecavir 0.5 mg), Compared to an Equivalent Dose of a Reference Drug Product (Baraclude 0.5mg Tablets) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yung Shin Pharm. Ind. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yung Shin Pharm. Ind. Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of a Test&#xD;
      Formulation of Entigin Film Coated Tablet 0.5mg (Entecavir 0.5 mg), Compared to an Equivalent&#xD;
      Dose of a Reference Drug Product (Baraclude 0.5mg Tablets) in Healthy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration(AUC)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax(Tmax)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Drug Concentration(Cmax)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life(T1/2)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the (first) moment plasma concentration-time curve(AUMC)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Residence Time(MRT)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>The safety was monitored throughout the study. Up to 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Entigin Film Coated Tablet 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entigin Film Coated Tablet 0.5mg Dosing Regimen: Single dosing of two tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baraclude 0.5mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baraclude 0.5mg Tablets Dosing Regimen: Single dosing of two tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entigin Film Coated Tablet 0.5mg</intervention_name>
    <arm_group_label>Entigin Film Coated Tablet 0.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(Baraclude 0.5mg Tablets</intervention_name>
    <arm_group_label>Baraclude 0.5mg Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult, aged between 20 to 45 years old.&#xD;
&#xD;
          2. Physically and mentally healthy subjects as confirmed by an interview, medical&#xD;
             history, clinical examination, laboratory tests, chest x-ray and electrocardiogram.&#xD;
&#xD;
               -  no particular clinical significance in clinical examination and laboratory tests&#xD;
                  within two months (60 days) prior to administration of study medication.&#xD;
&#xD;
               -  normal or considered not clinically significant by the investigator chest X-ray&#xD;
                  and Electrocardiogram (ECG) results within six months(180 days)prior to&#xD;
                  administration of study medication.&#xD;
&#xD;
          3. Body weight must be above 50 kg for male and 45 kg for female.&#xD;
&#xD;
          4. The normal range of the body mass index should be between 18 and 30; body mass index&#xD;
             equals [weight (kg)]/[height (m)]2.&#xD;
&#xD;
          5. Laboratory determinations results are within normal range or considered not clinically&#xD;
             significant by the investigator, including: Serum Glutamic Oxaloacetic Transaminase&#xD;
             (SGOT, same as AST), Serum Glutamic Pyruvic Transaminase (SGPT, same as ALT), albumin,&#xD;
             glucose, creatinine, uric acid, cholesterol, Triglycerides (TG),&#xD;
             Gamma-Glutamyl-Transpeptidase (Î³-GT), alkaline phosphatase, total bilirubin, Blood&#xD;
             Urea Nitrogen (BUN), Hepatitis B surface antigen (HBsAg), Anti-Hepatitis C virus (HCV)&#xD;
             and Anti-Human Immunodeficiency Virus (HIV) test.&#xD;
&#xD;
          6. Hematology test results are within normal range or considered not clinically&#xD;
             significant by the investigator, including: hemoglobin, hematocrit, White Blood Cell&#xD;
             (WBC) count, Red Blood Cell (RBC) count, platelet count and WBC count with&#xD;
             differential.&#xD;
&#xD;
          7. Urinalysis results are within normal range or considered not clinically significant by&#xD;
             the investigator, including: glucose, protein, RBC, WBC, epithelial cells, casts and&#xD;
             bacteria.&#xD;
&#xD;
          8. Female subject who is:&#xD;
&#xD;
               -  using adequate contraception since last menstruation and no plan for conception&#xD;
                  during the study.&#xD;
&#xD;
               -  non-lactating.&#xD;
&#xD;
               -  has negative pregnancy test (urine) prior to the study.&#xD;
&#xD;
          9. Informed consent form signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history of drug or alcohol abuse during the past 24 weeks.&#xD;
&#xD;
          2. Sensitivity to analogous drug.&#xD;
&#xD;
          3. A clinically significant illness (such as lactic acidosis or severe hepatomegaly with&#xD;
             steatosis) within the past 4 weeks.&#xD;
&#xD;
          4. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic,&#xD;
             neurological, pulmonary or gastrointestinal pathology within the past 4 weeks.&#xD;
&#xD;
          5. Planned vaccination during the time course of the study.&#xD;
&#xD;
          6. Participation of any clinical investigation during the last 60 days.&#xD;
&#xD;
          7. Regular use of any medication during the last 4 weeks.&#xD;
&#xD;
          8. Single use of any medication during the last 2 weeks.&#xD;
&#xD;
          9. Blood donation of more than 250 mL within the past 12 weeks.&#xD;
&#xD;
         10. Employees and their families of sponsor and/or Contract Research Organization (CRO)&#xD;
             company.&#xD;
&#xD;
         11. Individuals are judged by the investigator or co-investigator to be undesirable as&#xD;
             subjects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

